LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Gesloten

SectorGezondheidszorg

78.92 -1.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

78.05

Max

Belangrijke statistieken
By Trading Economics
Inkomsten	18M -69M
Verkoop	32M 34M
EPS	-0.71
Winstmarge	-201.467
Werknemers	253
EBITDA	18M -67M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+50.93% upside

Dividenden
By Dow Jones
Volgende Winsten	11 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-523M 6.6B
Vorige openingsprijs	80.18
Vorige sluitingsprijs	78.92

Nieuwssentiment

By Acuity

50%

159 / 345 Rangschikking in Healthcare

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

50.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 119.07 USD 50.93%

Hoogste 140 USD

Laagste 100 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Gebaseerd op 16 analisten die aandelenratings hebben gegeven aan Kymera Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

159 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.